Jane B. Acri, Ph.D. - Publications

Affiliations: 
Division of Pharmacotherapies and Medical Consequences of Drug Abuse National Institute on Drug Abuse 
Area:
Substance Abuse Disorders
Website:
http://www.usuhs.mil/mps/grunberg/labalumni.html

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Egli M, White DA, Acri JB. Considerations in the Evaluation of Potential Efficacy of Medications for Alcohol and Drug Use Disorders: An Editorial. International Review of Neurobiology. 126: 1-14. PMID 27055609 DOI: 10.1016/bs.irn.2016.02.007  0.76
2015 Appel NM, Li SH, Holmes TH, Acri JB. Dopamine D3 Receptor Antagonist (GSK598809) potentiates the hypertensive effects of cocaine in conscious, freely-moving dogs Journal of Pharmacology and Experimental Therapeutics. 354: 484-492. DOI: 10.1124/jpet.115.224121  0.76
2015 Skolnick P, White D, Acri JB. Emerging targets for stimulant use disorders: Where to invest in an era of constrained resources? Cns and Neurological Disorders - Drug Targets. 14: 691.  0.76
2015 Skolnick P, White D, Acri JB. Synopsis of expert opinions and conclusions Cns and Neurological Disorders - Drug Targets. 14: 773-776.  0.76
2013 Acri J. Evidence for the Contribution of D4 Receptors to Cocaine Self-Administration in Monkeys Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 180. DOI: 10.1016/B978-0-12-800044-1.00162-8  0.76
2008 Acri JB. Introduction to a Symposium on Recent Advances in the Development of Medications for Drug Abuse Treatment in Honor of Jack H. Mendelson, MD Experimental and Clinical Psychopharmacology. 16: 443-445. PMID 19086765 DOI: 10.1037/a0014102  0.76
2008 Acri JB, Chiang CN, McCann DJ, Shih ML, Vocci FJ. Summary of NIDA medications workshop: new opportunities for chemists and pharmacologists Drug and Alcohol Dependence. 92: 307-311. PMID 18286704 DOI: 10.1016/j.drugalcdep.2007.05.020  0.76
2008 McCann DJ, Acri JB, Vocci FJ. Drug discovery and development for reward disorders: Views from government Animal and Translational Models For Cns Drug Discovery. 3: 23-40. DOI: 10.1016/B978-0-12-373861-5.00022-9  0.76
2007 Elkashef A, Biswas J, Acri JB, Vocci F. Biotechnology and the treatment of addictive disorders: New opportunities Biodrugs. 21: 259-267. PMID 17628123 DOI: 10.2165/00063030-200721040-00006  0.76
2005 Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: The state of the science American Journal of Psychiatry. 162: 1432-1440. PMID 16055764 DOI: 10.1176/appi.ajp.162.8.1432  0.76
2001 Miller DK, Crooks PA, Teng L, Witkin JM, Munzar P, Goldberg SR, Acri JB, Dwoskin LP. Lobeline inhibits the neurochemical and behavioral effects of amphetamine. The Journal of Pharmacology and Experimental Therapeutics. 296: 1023-34. PMID 11181937  0.76
2001 Acri JB, Thompson AC, Shippenberg T. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse (New York, N.Y.). 39: 343-50. PMID 11169785 DOI: 10.1002/1098-2396(20010315)39:4<343::AID-SYN1018>3.0.CO;2-Q  0.76
1998 Izenwasser S, Acri JB, Kunko PM, Shippenberg T. Repeated treatment with the selective kappa opioid agonist U-69593 produces a marked depletion of dopamine D2 receptors. Synapse (New York, N.Y.). 30: 275-83. PMID 9776131 DOI: 10.1002/(SICI)1098-2396(199811)30:3<275::AID-SYN5>3.0.CO;2-8  0.76
1998 Witkin J, Gasior M, Acri J, Beekman M, Thurkauf A, Yuan J, DeBoer P, Wikström H, Dijkstra D. Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907. European Journal of Pharmacology. 347: R1-3. PMID 9741997 DOI: 10.1016/S0014-2999(98)00174-5  0.76
1997 Acri JB, Wong G, Lyon T, Witkin JM, Basile AS. Localization and pharmacological characterization of pigeon diazepam-insensitive GABAA receptors. Neuroscience. 77: 371-8. PMID 9472397 DOI: 10.1016/S0306-4522(96)00469-1  0.76
1997 Geter-Douglass B, Katz JL, Alling K, Acri JB, Witkin JM. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists. The Journal of Pharmacology and Experimental Therapeutics. 283: 7-15. PMID 9336302  0.76
1997 Witkin JM, Acri JB, Gleeson S, Barrett JE. Blockade of behavioral effects of bretazenil by flumazenil and ZK 93,426 in pigeons. Pharmacology, Biochemistry, and Behavior. 56: 1-7. PMID 8981602 DOI: 10.1016/S0091-3057(96)00120-7  0.76
1996 Acri JB, Serdikoff SL, Witkin JM, Sannerud CA. Discriminative stimulus effects of the benzodiazepine receptor partial agonist bretazenil in pigeons and in rats. Behavioural Pharmacology. 7: 72-77. PMID 11224396  0.76
1996 Witkin JM, Acri JB, Wong G, Gleeson S, Barrett JE. Behavioral and biochemical characterization of benzodiazepine receptor partial agonists in pigeons. The Journal of Pharmacology and Experimental Therapeutics. 277: 87-96. PMID 8613971  0.76
1996 Acri JB, Siedleck BK, Witkin JM. Effects of benztropine on behavioral and toxic effects of cocaine: comparison with atropine and the selective dopamine uptake inhibitor 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-propyl)-piperazine. The Journal of Pharmacology and Experimental Therapeutics. 277: 198-206. PMID 8613919  0.76
1996 Acri JB, Shah JH, Newman AH, Belov YP, Basile AS, Sharpe LG, Witkin JM. Behavioral effects and dopamine antagonist properties of N-alkylaminobenzazepines Drug Development Research. 37: 39-47. DOI: 10.1002/(SICI)1098-2299(199601)37:1<39::AID-DDR2>3.0.CO;2-N  0.76
1995 Witkin JM, Acri JB. Effects of ifenprodil on stimulatory, discriminative stimulus, and convulsant effects of cocaine. Behavioural Pharmacology. 6: 245-253. PMID 11224333  0.76
1995 Acri JB, Brown KJ, Saah MI, Grunberg NE. Strain and age differences in acoustic startle responses and effects of nicotine in rats. Pharmacology, Biochemistry, and Behavior. 50: 191-8. PMID 7740057 DOI: 10.1016/0091-3057(94)00285-Q  0.76
1995 Acri JB, Carter SR, Alling K, Geter-Douglass B, Dijkstra D, Wikström H, Katz JL, Witkin JM. Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. European Journal of Pharmacology. 281: R7-9. PMID 7589197 DOI: 10.1016/0014-2999(95)00411-D  0.76
1995 Acri JB, Wong G, Witkin JM. Stereospecific transduction of behavioral effects via diazepam-insensitive GABAA receptors. European Journal of Pharmacology. 278: 213-23. PMID 7589157 DOI: 10.1016/0014-2999(95)00128-8  0.76
1994 Acri JB. Nicotine modulates effects of stress on acoustic startle reflexes in rats: dependence on dose, stressor and initial reactivity Psychopharmacology. 116: 255-265. PMID 7892414 DOI: 10.1007/BF02245326  0.76
1994 Acri JB, Morse DE, Popke EJ, Grunberg NE. Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology. 114: 369-74. PMID 7838931 DOI: 10.1007/BF02244861  0.76
1992 Acri JB, Grunberg NE. A psychophysical task to quantify smoking cessation-induced irritability: the reactive irritability scale (RIS). Addictive Behaviors. 17: 587-601. PMID 1488939 DOI: 10.1016/0306-4603(92)90068-7  0.76
1991 Acri JB, Grunberg NE, Morse DE. Effects of nicotine on the acoustic startle reflex amplitude in rats. Psychopharmacology. 104: 244-8. PMID 1876669 DOI: 10.1007/BF02244186  0.76
1991 Grunberg NE, Acri JB. Conceptual and methodological considerations for tobacco addiction research. British Journal of Addiction. 86: 637-41. PMID 1859932  0.76
Show low-probability matches.